News of Note—Sanofi's Dengvaxia, flu vaccines and more

In this week's news of note, a Philippine FDA official said Sanofi knew of Dengvaxia risks earlier than it disclosed, but a company executive denied the allegation. (Pixabay)

Here is some other vaccine news of note for the week.

> An examination of documents filed in Singapore showed that Sanofi Pasteur was aware in October 2016 that Dengvaxia shouldn’t be given to those who haven’t had dengue, according to a Philippine official. A company executive said the document outlined possible or "theoretical" risks. CNN article | Inquirer article 

> The WHO has recommended changing two flu strains currently included in flu vaccines for the next season, and an FDA advisory committee will determine whether to apply them for the U.S. WHO recommendation | FDA statement


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Supported by a £4.7 million government award, the University of Liverpool is leading a collaborative project to develop a Zika vaccine suitable for pregnant women. Release

> Emergent BioSolutions and partner Valneva have advanced their Zika vaccine candidate into human testing. Release

> South Korea’s SK Chemicals, which recently licensed its cell-based flu vaccine technology to Sanofi, plans to spin off its vaccine business into a separate subsidiary. Korea Biomedical Review article

> The Association of the British Pharmaceutical Industry said a U.K. government proposal on the methodology used to assess immunization programs would make it harder for people to access vaccines. ABPI statement

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.